Gambaran Pola Terapi Penderita Limfadenitis Tuberkulosis di Rumah Sakit Al-Islam Bandung

Naufal Kautsar, Yani Triyani, Miranti Kania Dewi

Abstract


Abstract. Tuberculosis (TB) is a chronic infection caused by Mycobacterium Tuberculosis. Tuberculosis based on anatomical location is classified into two, namely pulmonary TB and extrapulmonary TB (TBEP). Location or organ most commonly affected is lymph node. Lymphadenitis TB becomes EPTB with the highest number of events. Lymphadenitis TB can be treated by taking a combination of at least four different medications. TB drug classification is divided into first and second line. This study aims to find out the description of theurapical patterns of lymphadenitis TB at Al-Islam Hospital in 2017. This research uses descriptive research design. The subjects used were lymphadenitis TB patients and the study material was taken from secondary data namely medical records at Al-Islam Hospital in 2017. Samples used were 22 data. The results in this study showed that as many as 9,1% were given first-line antituberculosis drugs therapy pattern and 90,9% were given second-line antituberculosis drugs. The most widely used pattern of therapy was second-line anti-tuberculosis drugs with combination 2 as many as 13 patients (59,1%). This can be caused by the patient’s resistance.

Keywords: Lymphadenitis TB, Theurapical Pattern, Anti-Tuberculosis Drug.

Abstrak. Tuberkulosis (TB) adalah infeksi kronis yang disebabkan oleh Mycobacterium Tuberculosis. Tuberkulosis berdasarkan lokasi anatomis diklasifikasikan menjadi 2, yaitu TB paru dan TB ekstraparu (TBEP). Lokasi atau organ yang paling sering terkena adalah kelenjar getah bening. Limfadenitis TB menjadi TBEP dengan jumlah kejadian terbanyak. Terapi limfadenitis TB dapat ditangani atua diobati dengan mengkonsumsi OAT yang terdiri dari kombinasi minimal empat macam obat. Klasifikasi obat anti tuberkulosis dibagi menjadi lini pertama dan lini kedua. Penelitian ini bertujuan untuk mengetahui gambaran pola terapi pasien limfadenitis TB di Rumah Sakit Al-Islam Bandung tahun 2017. Penelitian ini menggunakan desain penelitian deskriptif. Subjek yang digunakan adalah pasien limfadneitis TB dan bahan penelitian diambil dari data sekunder yaitu rekam medis di Rumah Sakit Al-Islam periode 2017. Sampel yang digunakan sebanyak 22 data. Hasil dalam penelitian ini menujukkan 9,1% diberikan pola terapi obat anti-tuberkulosis lini pertama dan 90,9% diberikan pola terapi OAT lini kedua. Pola terapi terbanyak yang diberikan adalah OAT lini kedua dengan kombinasi 2 yaitu sebanyak 13 pasien (59,1%). Hal ini dapat disebabkan karena pasien sudah resistensi.

Kata Kunci: Limfadenitis TB, Pola Terapi, Obat Anti Tuberkulosis.

Keywords


Limfadenitis TB, Pola Terapi, Obat Anti Tuberkulosis

Full Text:

PDF

References


Blomberg B, Spinaci S, Fourie B, Laing R. 2011. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ.

CDC. 2017. Drug-Resistant TB | TB |CDC.

CDC. 2016. Transmission and Pathogenesis of Tuberculosis.

Centers for Disease Control and Prevention. CDC. 2017. TB. Multidrug-Resistant Tuberculosis (MDR TB). Multidrug-Resistant Tuberc (MDR TB).

Khandkar C, Harrington Z, Jelfs PJ, Sintchenko V, Dobler CC. 2015. Epidemiology of peripheral lymph node tuberculosis and genotyping of M. tuberculosis strains.

MIMS Indonesia Referensi Obat. 2018. Levofloxacin.

Mohapatra PR, Janmeja AK. 2009. Tuberculous lymphadenitis. J Assoc Physicians India.

Pagliotto, Aline Daniele Furlan Caleffi-Ferracioli. 2016. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination. Journal of Microbiology, Immunology and Infection.

Popescu MR, Calin G, Strambu I, Olaru M, Balasoiu M, Huplea V, et al. 2014. Lymph node tuberculosis – an attempt of clinico- morphological study and review of the literature. Rom J Morphol Embryol.

Purohit MR, Mustafa T, Mørkve O, Sviland L. 2009. Gender differences in the clinical diagnosis of tuberculous lymphadenitis-a hospital-based study from Central India. Int J Infect Dis.

Ramirez-Lapausa M, Menendez-Saldana A, Noguerado-Asensio A. 2015. Extrapulmonary tuberculosis: an overview. Rev Esp Sanid Penit.

Robbins Basic Pathology. Kumar, Abbas, Aster, Penyunting. 2011. Transmission and Dissemination Microbes. Pathological Disease. Edisi ke-9. Canada: Elsevier.

Subuh M, Priohutomo S, Widaningrup C, Dinihari TN, Siaglan V. 2014. Pedoman Nasional Pengendalian Tuberkulosis. Pedoman Nasional Pengendalian Tuberkulosis.

Tiberi S, Scardigli A, Centis R, D’Ambrosio L, Muñoz-Torrico M, Salazar-Lezama MÃ, et al. 2017. Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis.

Vasankari T, Holmström P, Ollgren J, Liippo K, Ruutu P. 2010. Treatment outcome of extra-pulmonary tuberculosis in Finland: a cohort study. BMC Public Health.

WHO. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis.

WHO. 2014. Handbook C, The TO, Guidelines WHO, The FOR, Management P, Tuberculosis OFD. Kanamycin (Km).

WHO. 2018. Tuberculosis. World Health Organization.




DOI: http://dx.doi.org/10.29313/kedokteran.v0i0.12825

Flag Counter    Â